Damora Therapeutics Inc DMRA

US Biotechnology

$28.99 ▼ -0.75% ($-0.22)

📅 Earnings This Week

Open $29.21

Prev Close $29.21

Day Range $28.65 – $30.27

52W Range $16.50 – $34.89

Market Cap $1.78B

Beta -4.13

EPS (TTM) $-141.43

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2020-10-29
Shares Out.	61,550,000
Website	galecto.com/ ↗
Phone	13026587581
Employees	7
Net Income	-$27.8M
Total Assets	$535.4M
Total Liabilities	$23.8M
Equity	$510.3M

About Damora Therapeutics Inc

Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.

Damora Therapeutics Inc is a publicly traded company under the ticker symbol DMRA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.